



N° 4 - Jan 2023

news

Welcome to the fourth edition of the biannual Newsletter dedicated to Pharmas/ Biotechs.

Partner of your projects and challenges for several years, please find here our newest technologies: *Lumit™ Immunoassay technology for phospho-protein levels, Organoid applications for Cell Health Assays, NanoLuc In Vivo Imaging, Tools portfolio available for QC batch release of Biodrugs or vaccines, Custom capabilities, New SARS-CoV-2 PsVLP assay variants & New R&D developments for HiBiT Delivery Assay - Live-cell measurement.*

Stay connected! And enjoy the winter read!

Promega's Teams

Pharmas Biotechs

Contents:

About Promega

Innovations

Connections

ABOUT PROMEGA



Discover our Manufacturing Center: the Feynman Center

Named for Nobel Prize winning physicist Richard Feynman, is a 24 340m² facility primarily devoted to cGMP manufacturing of molecular biology reagents for In Vitro Diagnostic assays. Built in 2014, the space accommodates large-, medium- and small-scale bulk formulation, including the manufacture of DNA purification reagents, as well as product dispensing, and automated and manual kit packaging. Feynman also houses Quality Control labs and Document Control.

From simple changes in product size or packaging to development of custom assays and high-throughput solutions, our custom offerings cover a breadth of capabilities in manufacturing, technology development, assay automation and inventory management.

When you partner with Promega you gain access to a team of scientists and experts dedicated to supporting your success. We are here to collaborate with you to create the solution that you need.

[Read more](#)



Download Digital Version



#1 - NEWS FROM

Small Molecule Drug Discovery

Lumit™ Immunoassay Cellular Systems – Complete Assays

No-wash bioluminescent immunoassay for Fast Quantification of Phosphorylated or Total Protein:

- Homogeneous and simple (add and read only, no wash formats)
- Low sample volume (5-25µl)
- Sensitive assays with wide dynamic range
- Fast Incubation and Detection times (90-120 min)
- No special equipment required (luminometer)
- Amenable to high throughput applications




Description	Components	Size (w/v/v)	CS#
Lumit™ pERK (T1820) Immunoassay Cellular System	Lumit pERK (T1820) Antibodies Immunoassay Cellular System, Set 1	100 L,000	C3397A03
Lumit™ pAKT (Ser473) Immunoassay Cellular System	Lumit pAKT (Ser473) Antibodies Immunoassay Cellular System, Set 1	100 L,000	C3397A04
Lumit™ pS7AT2 (Tyr705) Immunoassay Cellular System	Lumit pS7AT2 (Tyr705) Antibodies Immunoassay Cellular System, Set 1	100 L,000	C3397A08
Lumit™ pAkt (Ser32) Immunoassay Cellular System	Lumit pAkt (Ser32) Antibodies Immunoassay Cellular System, Set 1	100 L,000	C3397A11
Lumit™ pERK (Tyr223) Immunoassay Cellular System	Lumit pERK (Tyr223) Antibodies Immunoassay Cellular System, Set 1	100 L,000	C3397A15
Lumit™ pAkt (Tyr223) Immunoassay Cellular System	Lumit pAkt (Tyr223) Antibodies Immunoassay Cellular System, Set 1	100 L,000	C3397A19
Lumit™ pERK (Tyr223) Immunoassay Cellular System	Lumit pERK (Tyr223) Antibodies Immunoassay Cellular System, Set 1	100 L,000	C3397A20

Organoid Applications for Cell Health Assays

Combining biologically relevant cell culture models with user-friendly and sensitive assay systems will yield rapid, cost-effective, and predictive research results:


- Monitoring of viability/cytotoxicity changes with Cell Health Solutions optimized for advanced 3D in vitro cell culture systems
- Confirming Apoptosis
- Real-time tracking possible
- Multiplexing options
- Compatible with Matrigel



NanoLuc In Vivo Imaging

The Nano-Glo® In Vivo Substrate (FFz), is an optimized reagent designed specifically for in vivo detection of NanoLuc® Luciferase, NanoLuc® fusion proteins, or reconstituted NanoBIT® Luciferase.

This aqueous soluble reagent provides increased substrate bioavailability in vivo, leading to bright signals, and has handling requirements compatible with in vivo workflows (IV or IP substrate delivery).




#2 - NEWS FROM

Biologics Development & QC batch release

Tools portfolio available for QC batch release of Biologics or vaccines

- Genomic Reagents to support your nucleic acid production & extraction/purification
- Cell Health Solutions to monitor cell viability/cytotoxicity during Bioproduction
- Bioanalytical tools for antibody purification, internalization and Mass Spectrometry analysis of your biologics

Broader functional Cell-based Bioassays portfolio to support your potency QC: Thaw-and-Use and Cell Propagation Model formats are produced under full Quality Control (under ICH Q6B guidelines).



Custom TRS capabilities for Biologics Assay Development and Services

Including new assay development, modification of existing assays, bioassay optimization and qualification, biologic drug profiling and custom cell manufacturing.



Speed up your workflow and improve your clients' drug discovery and development using industry-leading Promega technologies!




Manufacturing and Quality Systems
Promega functional bioassays and protein characterization products are manufactured in our global state-of-the-art facilities. Over 450,000 square feet of environmentally controlled manufacturing spaces allow flexible bulk manufacture with capabilities for custom automated or semi-automated filling and packaging. We are prepared to accommodate your needs; from bulk production through final product finishing.



New SARS-CoV-2 HiBiT-PsVLP assays based on Bioluminescence to measure the activity of small molecule inhibitors and neutralizing antibodies that block viral entry into the host cell

Advantages:

1. Increased biosafety (BSL-1):
 - PsVLPs are non-replicating and lack viral nucleic acid
2. Simple and rapid:
 - Add-mix-read protocol with short TAT (<5 hours)
 - Monitor viral entry in live cells
3. Convenient:
 - Available in Thaw-and-Use kit format
 - No need to generate virus or culture cells
4. Quantitative assay readout



Different variants available enables comparison of SARS-CoV-2 variants: G614, alpha, beta, gamma, delta, omicron


Product	Kit size	Part #
Ready to order HiBiT-PsVLPs		
SARS-CoV-2 S(G614) HiBiT-PsVLPs	1X 5X	CS329501 CS329502
SARS-CoV-2 S(Delta) HiBiT-PsVLPs	1X 5X	CS329509 CS329510
SARS-CoV-2 S(Omicron) HiBiT-PsVLPs	1X 5X	CS329533 CS329534
SARS-CoV-2 S(Omicron BA.4/5) HiBiT-PsVLPs	1X 5X	CS329537 CS329538
VSV-G HiBiT-PsVLPs (Control)	1X 5X	CS329517 CS329518
Ready to order HiBiT-PsVLPs		
SARS-CoV-2 S(Alpha) HiBiT-PsVLPs	1X 5X	CS329503 CS329504
SARS-CoV-2 S(Gamma) HiBiT-PsVLPs	1X 5X	CS329505 CS329506
SARS-CoV-2 S(Epsilon) HiBiT-PsVLPs	1X 5X	CS329507 CS329508
SARS-CoV-2 S(Zeta) HiBiT-PsVLPs	1X 5X	CS329511 CS329512
SARS-CoV-2 S(Iota) HiBiT-PsVLPs	1X 5X	CS329513 CS329514
SARS-CoV-2 S(Kappa) HiBiT-PsVLPs	1X 5X	CS329515 CS329516
SARS-CoV-2 S(Lambda) HiBiT-PsVLPs	1X 5X	CS329535 CS329536

Technology Adaptable For Other Viral Target!
some tools already available for Ebola

SARS-CoV-2 (Omicron BA.4/5) HiBiT-PsVLPs Now Available!

[Download poster](#)
[Read more](#)

HiBIT Delivery Assay: Live-cell measurement of internalization of HiBIT-tagged molecules into the cytosol of LgBIT-expression cells:




Measure rate of POI-HiBIT delivery to cytosol in real time

1. LgBIT subunit is expressed in the target cell
2. Incubate a HiBIT-tagged protein or peptide with cells and allow it to internalize
3. LgBIT inside cell binds HiBIT to reconstitute NanoBIT enzyme
4. Use washes and/or DrkBIT peptide to inhibit extracellular NanoBIT complex
5. Add Nano-Glo® Live Cell Reagent and read with a luminometer

Concept can be adapted for all entities (proteins, peptides, oligos, virus, other pathogens...) and applications!

Immuno-Fluorescence analysis possible using anti-HiBit and/or anti-LgBIT antibodies to track protein translocation in living cells (PoC ongoing on different targets).



Immuno fluorescence detection of LgBIT fusion proteins expressed in HeLa cells.

[Download product application](#)
[Request a meeting with R&D](#)

LAST WEBINARS

From Cell Culture to Bioluminescence Analysis (FR)
Eppendorf / Promega - Dec. 1st, 2022 - Replay



Florian Mignot, Cell Based Assay Specialist, Promega



Jérémy Schilling, Account Manager Auvergne - Rhône Alpes & Alsace, Eppendorf

[Replay](#)

Accelerate your PCR with high quality results (FR)
Eppendorf / Promega - Oct. 18, 2022 - Replay



Emmanuelle Killian, Genomics and Sequencing Product Manager, Promega



David Gaertner, Product Marketing Manager Europe, Eppendorf

[Replay](#)

Bioanalytical Tools for Biosimilar Development
Promega - Aug. 10, 2022 - Replay



Jeff Nelson PhD, Biologics Product Manager, Promega Corporation

[Replay](#)

Keeping it Real: Why P450 Assays are Required to Predict Human Drug Responses Using Liver-on-a-Chip

CN-Bio / Promega - Oct. 11, 2022 - Replay



Darren Heywood, PhD, Product Manager, Cell Health, Promega UK



Atefeh Mobasser, PhD, Field Application Scientist, CN-Bio

[Replay](#)

Lumit Technology forum: Simplify your workflow and yield faster results!


Promega - Nov. 8, 2022 - Replay



Vincent Van Hee PhD, Client Support Specialist, Promega

[Replay](#)

EVENTS / NETWORKS



... And more soon!
Stay connected! ...

LAST NEWS

10 years of NanoLuc!

NanoLuc® Luciferase is a tiny, luminous reporter enzyme that has transformed the face of molecular biology in the ten years since its discovery. Derived from a species of deep-sea shrimp and 100 times brighter than firefly luciferase, the possibilities of NanoLuc® are seemingly endless. Learn more about the vast range of capabilities for this little enzyme: https://link.in/qUG4XT_Q

Here are some citations using HiBIT technology in neuroscience:

Institution	Title
Gifu Pharmaceutical University, Japan	Partial reduced Pi transport function of P1T-2 might not be sufficient to induce brain calcification of idiopathic basal ganglia calcification. https://doi.org/10.1038/s41598-019-53401-0
Gifu Pharmaceutical University, Japan	SLC20A2 variants cause dysfunctional phosphate transport activity in endothelial cells induced from Idiopathic Basal Ganglia Calcification patients-derived iPSCs. https://doi.org/10.1016/j.bbrc.2019.01.096
University of Iowa, USA	Regions of MRAP2 required for the inhibition of orexin and prokineticin receptor signaling
University of Regensburg, Germany	Chronic oxytocin-driven alternative splicing of Crfr2a induces anxiety. https://doi.org/10.1038/s41386-021-01141-x
Luxembourg Institute of Health	The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides
University of Antwerp, Belgium	Loss of PPP6 in neurodegenerative dementia: a genetic player in the dysfunction of neuronal excitability https://doi.org/10.1007/s00401-019-01976-3
University of Pisa, Italy and University of Berlin, Germany	Non-functional trace amine-associated receptor 1 variants in patients with mental disorders
University of Berlin, Germany	Different signaling profiles of MC4R mutations with three different ligands. https://doi.org/10.3390/jms21041224
Scripps FL	The role of orphan receptor GPR139 in neuropsychiatric behavior https://doi.org/10.1038/s41386-021-00962-2
Scripps FL and UWashington, USA	Pitcd1 mediates opioid tolerance via cholesterol-dependent effects on μ -opioid receptor trafficking https://doi.org/10.1038/s41593-022-01135-0
Abbvie (US and GmbH)	Pharmacological mTOR-inhibition facilitates clearance of AD-related tau aggregates in the mouse brain https://doi.org/10.1016/j.jepihp.2022.175301
Institute of Green BioScience and Technology, Korea	Positive Correlation between nNOS and Stress-Activated Bowel Motility Is Confirmed by In Vivo HiBIT System. https://doi.org/10.3390/cells10051028

DON'T MISS

Biolabs

In continuation of the successful partnership already established for several years between Promega Corp & Biolabs US,

Promega France is excited to share with you that we both agreed to extend this collaboration in France as a General Sponsor for the future Biolabs incubators: Spartners & Hôtel Dieu

As already observed in USA, we are convinced that this will help these Biotech companies to accelerate their R&D activities and projects.



A new Biotech Program from January 2023, a perfect program to accelerate your drug discovery.

Come and discover it at: <https://france.promega.com/c/biotech-program/>

- Privileged support
- Webinars & trainings, on demand
- Special first order offer -50%*
- Easier access to equipment
- Special discounts for start-up
- Support for assay & tools development



Contact us

Want to learn more about our latest technologies ?

Organize a webinar, an onsite workshop or seminar ?

Need technical support ?


We are here to help !

[**FR.support@promega.com**](mailto:FR.support@promega.com)

0 800 488 000

Or contact your local Key Account Manager






**Fc Effector Activity
Cell Health Assays**

**Cytokine & Growth
Factor Bioassays**

Monoclonal Ab

**Discover all the
Biologics portfolio**



**Antibody Internalization Assays
Cell Health Assays**



Fc Effector Activity

Reporter Bioassays

FcγRIIIa-VADCC
 FcγRIIIa-F ADCC
 mFcγRIV ADCC
 mFcγRIII ADCC
 FcγRIIIa-H ADCP
 FcγRIIIa-R ADCP
 FcγRI ADCP
 THP-1 ADCP
 FcγRIIb
 CD38-KO ADCC

Target Cells

SARS-CoV-2 S Protein
 mTNFα
 mVEGF
 mRANKL
 PD-1
 CTLA-4

PBMC ADCC Bioassays

ADCC-Qualified PBMCs* +
 Raji Cells (HiBiT)
 Ramos Cells (HiBiT)
 A549 Cells (HiBiT)
 SK-BR-3 Cells (HiBiT)
 H929 Cells (HiBiT)
 *Also sold as stand-alone

Immunoassays

FcRn
 FcγRI
 FcγRIIIa-H131, FcγRIIIa-R131
 FcγRIIIa-V158, FcγRIIIa-F158

Updated: August 2022

Immune Checkpoint Modulation

Reporter Bioassays

Co-Inhibitory Receptors:

PD-1/PD-L1
 mPD-1/PD-L1
 PD-1/PD-L2
 CTLA-4
 LAG-3/MHCI1
 TIM-3
 TIGIT/CD155
 CD112R/CD112
 TIGIT/CD112
 CD226/CD155
 ICOS Blockade
 CD28 Blockade
 BTLA/HVEM
 SIRPα/CD47
 LILRB2 (ILT4/HLA-G)
 Co-Stimulatory Receptors:

GITR
 4-1BB (CD137)
 OX40
 mOX40
 CD40
 ICOS Agonist
 CD28 Agonist
 HVEM/LIGHT
 CD27
 DR3

Combinations:

PD-1+TIGIT
 PD-1+LAG-3, PD-1+CTLA-4
 PD-1+4-1BB, PD-1+OX40 (T&U)

Accessory Cells

FcγRIIb CHO-K1 Cells
 FcγRIIb aAPC/CHO-K1 Cells
 aAPC/CHO-K1 Cells

BOLD = Catalog Product
BLACK = Early Access Material
italics = In Development

T Cell Retargeting (Bispecific Ab, CAR/TCR Therapy)

Reporter Bioassays

T Cell Activation (NFAT)
 T Cell Activation (IL-2)
 T Cell Activation (NFκB)

TCR Knock-Out Bioassays

TCRαβ-KO (CD4+) Bioassay
 TCRαβ-KO (CD8+) Bioassay
 TCRαβ-KO (CD4+CD8+) Bioassay
 TCRαβ-KO (CD4:CD8-) Bioassay
 DMF5 TCRαβ-KO (CD8+) Bioassay
 Other TCR-engineered TCRαβ-KO Bioassays

CD8+ T Cell Cytotoxicity Assays

TDOCC-Qualified Primary CD8+ T Cells +
 HiBiT Target Cells (see list below)

General Target Cell Killing

Customer Effector Cells +

K562 Cells (HiBiT)
 Raji Cells (HiBiT)
 Raji +/- CD19 Cells (HiBiT)
 Ramos Cells (HiBiT)
 Ramos +/- CD19 Cells (HiBiT)
 A549 Cells (HiBiT)
 SK-BR-3 Cells (HiBiT)
 U937 Cells (HiBiT)
 H929 Cells (HiBiT)
 OVCAR3 Cells (HiBiT)
 SKOV3 Cells (HiBiT)
 T2 Cells (HiBiT)
 SARS-CoV-2 S Protein CHO-K1 Cells (HiBiT)
 mTNFα CHO-K1 Cells (HiBiT)
 K562 Cells (HiBiT)
 CD19 K562 Cells (HiBiT)
 BCMA K562 Cells (HiBiT)

Immunoassays

IL-2, IFNγ, other cytokines

Cytokine, Growth Factor & Other Target Modulation

Reporter Bioassays

IL-1
 IL-2
 IL-2Rβγ
 IL-4
 IL-6
 IL-7
 IL-10
 IL-12
 IL-13
 IL-15
 IL-17
 IL-21
 IL-22
 IL-23
 VEGF
 VEGFR1
 BCMA
 TGF-β
 RANKL
 TPO Receptor (Nplate)
 TLR (1, 2, 4, 5, 6, 7, 8)

Reporter Cell Lines

TNFα
 IFNα/IFNβ, IFNγ
 EPO
 GM-CSF
 EGF
 G-CSF
 ARE-luc2P/INCI-H292

HiBiT PsVLP Bioassays

SARS-CoV-2

G614, Delta, Omicron, additional variants
 Additional viruses – please inquire

